Sangamo BioSciences | SGMO - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Alaunos Therapeutics USD 1.01M 175K 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Alterity Therapeutics Limited AUD 8.67M 893.38K 2025-12
Amgen USD 4.78B 1.12B 2026-03
Bayer EUR 9.88B 452M 2026-03
BioCryst Pharmaceuticals USD -553.84M 700.01M 2026-03
Biogen USD 1.96B 69.6M 2026-03
BioMarin Pharmaceutical USD 636.56M 39.61M 2026-03
Cipla INR 59.27B 1.71B 2026-03
Clal Biotechnology ILS 5.15M 9.47M 2022-12
Compugen USD 11.19M 96K 2026-03
CSL USD 5.7B 2.82B 2025-12
Gilead Sciences USD 23.52B 18.55B 2026-03
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Grifols EUR 1.99B 217.4M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Merck USD 18.17B 8.01B 2026-03
Novartis USD 9.29B 507M 2026-03
Omeros USD 59.16M 20.13M 2024-06
Pfizer USD 90.1B 77.19B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.31B 1.2B 2026-03
Sarepta Therapeutics USD 372.37M 480.65M 2026-03
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03